<PAGE>
* CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY THE
BRACKETS, HAS BEEN OMITTED AND FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
EXHIBIT 10.94
DESCRIPTION OF
AMENDMENT NO. 1 TO
AMENDED AND RESTATED PROMOTION AGREEMENT
The following is a description of Amendment No. 1 to the Amended
and
Restated Promotion Agreement, dated as of
December 16, 2001, by and among Wyeth,
a Delaware corporation (formerly American
Home Products Corporation, "Wyeth"),
Amgen Inc., a Delaware corporation
("Amgen"), and Immunex Corporation, a
Washington corporation and wholly-owned
subsidiary of Amgen ("Immunex") (the
"Promotion Agreement"). For purposes of the
Amendment, all capitalized terms
used but not otherwise defined in the
Amendment shall have the meanings assigned
to them in the Promotion Agreement. The
Amendment is effective as of July 8,
2003. The Amendment is limited and does not
constitute a modification,
acceptance or waiver of any other provision
of the Promotion Agreement.
Wyeth, Amgen, and Immunex amended the
Promotion Agreement by inserting the
following provision as a new Section
6.1(e):
"6.1(e) Additional Spending.
Notwithstanding anything to the contrary in this
Agreement, the Parties approve $[*] (U.S.
Dollars) in spending in 2003 for
promotion, sales and marketing activities
and for the medical
